Skip to content
Tenfell
Awarded contract
Published 21 Jul 2026

NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026

NHS England · London

Key facts

Awarded
05 Jul 2026
Contract starts
31 Aug 2026
Contract ends
31 Aug 2028
Procedure
Open procedure (framework)
Buyer type
Central government

Awarded to 24 suppliers

SupplierValue
CST Pharma Ltd—
GlaxoSmithKline—
Orifarm UK—
Pfizer Ltd—
Teva UK Ltd—
Viatris UK Healthcare Ltd—
Bayer plc—
Amgen Ltd—
Chugai Pharma Uk Ltd—
Napp Pharmaceuticals—
Sandoz Ltd—
Thornton & Ross Ltd—
Accord-UK Ltd—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Merck Serono Limited—
Novo Nordisk—
Roche Products Ltd—
Milpharm Limited—
Pharmacosmos UK Ltd—
Vifor Pharma UK Limited—
Biogen Idec Ltd.—
Aventis Pharma Limited t/a Sanofi—
LABORATORIES JUVISE PHARMACEUTICALS—

Description

NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East. Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months. Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Find a Tender (Open Government Licence v3.0). Always read the original notice before responding.